ArQule News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

10.12.19	Top Gainers: THOR Acquired, FTSV Up On Magrolimab Data, Investors Believe FATE (RTTNews)
09.12.19	Had You Invested In ArQule (ARQL) In June,... (RTTNews)
09.12.19	Merck To Acquire ArQule For $20/share In Cash - Quick Facts (RTTNews)
09.12.19	ArQule Announces Final Phase 1 Clinical Data for Its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting (Businesswire)
25.11.19	ArQule to Present Clinical Data for its Reversible BTK Inhibitor, ARQ 531, at the American Society of Hematology 2019 Annual Meeting (Businesswire)
30.10.19	EARNINGS SUMMARY: Details of ArQule Inc. Q3 Earnings Report (RTTNews)
30.10.19	ArQule Reports Third Quarter 2019 Financial Results (Businesswire)
29.10.19	ArQule Presents Recent Data on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Businesswire)
16.10.19	ArQule to Report Third Quarter 2019 Financial Results on October 30, 2019 (Businesswire)
16.10.19	ArQule Announces Presentations on ARQ 751 at the 2019 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (Businesswire)
08.10.19	ArQule to Present Preclinical Data on Miransertib for the Treatment of Vascular Malformations at the 2019 American Society of Human Genetics (ASHG) Annual Meeting (Businesswire)
26.09.19	ArQule to Present at the 2019 Cantor Global Healthcare Conference on October 3, 2019 (Businesswire)
17.09.19	ArQule to Participate in the Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease Companies on September 24, 2019 (Businesswire)
10.09.19	5 Top Losers In Healthcare Sector (NTRP, AKRO, SAVA...) (RTTNews)
28.08.19	ArQule to Participate in Citi’s 14th Annual Biotech Conference on September 4, 2019 (Businesswire)
07.08.19	EARNINGS SUMMARY: Details of ArQule Inc. Q2 Earnings Report (RTTNews)
07.08.19	ArQule Reports Second Quarter 2019 Financial Results (Businesswire)
05.08.19	ArQule to Participate in the BTIG Biotechnology Conference on Monday, August 12, 2019 (Businesswire)
01.08.19	ArQule to Present at the SVB Leerink Spotlight Series: Rare & Genetic Diseases on August 8, 2019 (Businesswire)
24.07.19	ArQule to Report Second Quarter 2019 Financial Results on August 7, 2019 (Businesswire)
27.06.19	ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (Businesswire)
25.06.19	ArQule Announces Pricing of $90 Million Public Offering of Common Stock (Businesswire)
24.06.19	ArQule Announces Commencement of Proposed Public Offering of Common Stock (Businesswire)
18.06.19	ArQule to Present at the BMO Prescriptions for Success Healthcare Conference on June 25, 2019 (Businesswire)
10.06.19	ArQule Announces Oral Presentation for its Pan-AKT Inhibitor, Miransertib, at the 2019 European Society of Human Genetics (ESHG) Conference (Businesswire)
07.06.19	ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 24th Congress of the European Hematology Association (EHA) (Businesswire)
30.05.19	ArQule to Present at the Jefferies 2019 Healthcare Conference on June 6, 2019 (Businesswire)
15.05.19	ArQule to Present at the 20th Annual B. Riley FBR Institutional Investor Conference on May 22, 2019 (Businesswire)
14.05.19	ArQule to Present at the 2019 RBC Capital Markets Global Healthcare Conference on May 21, 2019 (Businesswire)
08.05.19	ArQule to Present at the Bank of America Merrill Lynch 2019 Health Care Conference on May 15, 2019 (Businesswire)
01.05.19	EARNINGS SUMMARY: Details of ArQule Inc. Q1 Earnings Report (RTTNews)
01.05.19	ArQule Reports First Quarter 2019 Financial Results (Businesswire)
17.04.19	ArQule to Report First Quarter 2019 Financial Results on May 1, 2019 (Businesswire)
02.04.19	ArQule to Present at 18th Annual Needham Healthcare Conference on April 9, 2019 (Businesswire)
15.03.19	ArQule Announces Management Team Changes (Businesswire)
13.03.19	ArQule to Present at Oppenheimer’s 29th Annual Healthcare Conference on March 20, 2019 (Businesswire)
11.03.19	ArQule to Participate in the 31st Annual ROTH Conference on March 17-19, 2019 (Businesswire)
08.03.19	9 Top Gainers In Healthcare Sector (BPTH, ARQL, SEEL…) (RTTNews)
07.03.19	ArQule Reports Fourth Quarter and Full Year 2018 Financial Results (Businesswire)
25.02.19	ArQule Announces Publication of Clinical Data with Miransertib in Proteus Syndrome (Businesswire)
21.02.19	ArQule to Report Fourth Quarter and Full Year 2018 Financial Results on March 7, 2019 (Businesswire)
21.02.19	ArQule to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019 (Businesswire)
24.01.19	Basilea Announces Collaboration to Study Derazantinib and Atezolizumab (Tecentriq®) in Urothelial Cancer (Businesswire)
09.01.19	Basilea Announces Positive Interim Results from Registrational Phase 2 Study with Oncology Drug Candidate Derazantinib in Intrahepatic Cholangiocarcinoma (iCCA) (Businesswire)
19.12.18	ArQule Added to the NASDAQ Biotechnology Index (Businesswire)
03.12.18	ArQule Announces Clinical Data from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies at the 2018 ASH Annual Meeting (Businesswire)
01.12.18	ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting (Businesswire)
29.11.18	ArQule to Host Analyst Call Highlighting Clinical Progress from Ongoing Phase 1 Study of Reversible BTK Inhibitor, ARQ 531, in Patients with Relapsed/Refractory Hematologic Malignancies (Businesswire)
19.11.18	ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 2018 American Society of Hematology (ASH) Annual Meeting (Businesswire)
16.11.18	ArQule Presents Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ArQule Inc.

Aktien Top/Flop

Meistgelesene Nachrichten